North America Benign Prostatic Hyperplasia Devices Market, By Procedure Type (Transurethral Resection of the Prostate (TURP), Prostatic Urethral Lift (PUL), Prostatectomy, Laser Surgery, Transurethral Microwave Therapy (TUMT), Transurethral Needle Ablation of the Prostate (TUNA), Prostatic Stenting/Implants, Others), End-User (Hospitals and Clinics, Ambulatory Surgical Centers, Others) - Industry Trends and Forecast to 2030.
North America Benign Prostatic Hyperplasia Devices Market Analysis and Size
The North America benign prostatic hyperplasia (BPH) devices market is growing for several reasons, driven by a combination of demographic, technological, and healthcare factors. Benign Prostatic Hyperplasia refers to the non-cancerous enlargement of the prostate gland, which can cause urinary symptoms in men. The aging demographic in North America is a significant driver. As men age, the risk of developing BPH increases. With a larger elderly population, there is a higher prevalence of BPH cases, leading to greater demand for BPH devices and treatments.
Data Bridge Market Research analyses that the North America benign prostatic hyperplasia devices market which was USD 7,900.00 million in 2022, would rocket up to USD 20,126.01 million by 2030, and is expected to undergo a CAGR of 12.40% during the forecast period. This indicates the market value. “Transurethral Resection of the Prostate (TURP)” dominates the procedure type segment of the North America benign prostatic hyperplasia devices market owing to the increasing investment in healthcare. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
North America Benign Prostatic Hyperplasia Devices Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015-2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
By Procedure Type (Transurethral Resection of the Prostate (TURP), Prostatic Urethral Lift (PUL), Prostatectomy, Laser Surgery, Transurethral Microwave Therapy (TUMT), Transurethral Needle Ablation of the Prostate (TUNA), Prostatic Stenting/Implants, Others), End-User (Hospitals and Clinics, Ambulatory Surgical Centers, Others)
|
|
Countries Covered
|
U.S., Canada, Mexico
|
|
Market Players Covered
|
KARL STORZ (Germany), OmniGuide Holdings, Inc. (U.S.), Olympus Corporation (Japan), Richard Wolf GmbH (Germany), Lumenis (Israel), Urologix, LLC (U.S.), Boston Scientific Corporation (U.S.), Coloplast Corp (U.S.), Medifocus Inc. (U.S.), biolitec AG (Germany), Teleflex Incorporated (U.S.), Urotech Devices (Singapore), BD (U.S.), PROCEPT BioRobotics Corporation (U.S.)
|
|
Market Opportunities
|
|
Market Definition
The benign prostatic hyperplasia (BPH) devices market is the segment of the healthcare industry that deals with the development, production, marketing, and distribution of medical devices and technologies specifically designed for the diagnosis and treatment of benign prostatic hyperplasia, also known as BPH or prostate gland enlargement.
North America Benign Prostatic Hyperplasia Devices Market Dynamics
Drivers
- Patient Preference for Minimally Invasive Procedures
Many patients prefer minimally invasive BPH treatments over traditional surgical options such as open prostatectomy. Minimally invasive procedures often result in shorter hospital stays, reduced recovery times, and fewer complications, making them more attractive to patients. Minimally invasive BPH procedures typically involve smaller incisions or no incisions at all. Patients experience less pain and discomfort compared to traditional open surgeries, making these procedures more attractive. Minimally invasive techniques often result in shorter hospital stays and quicker recovery times. Patients can return to their normal activities sooner, which is highly appealing, especially to those with busy lifestyles
- Government Approvals and Regulations
Regulatory approvals and support from government health agencies provide confidence to healthcare providers and patients in the safety and efficacy of BPH devices, driving their adoption. Government regulatory agencies, such as the U.S. Food and Drug Administration (FDA) in the U.S. and Health Canada, require thorough testing and assessment of BPH devices to ensure their safety and efficacy. These regulations build trust among healthcare providers and patients, encouraging the adoption of approved devices. The stringent regulatory requirements act as a barrier to entry for new and potentially unsafe or ineffective devices. Established companies with proven track records are more likely to meet these requirements, contributing to market stability and patient safety
Opportunities
- Comprehensive Care Solutions
Offering comprehensive care solutions that include BPH devices, pharmaceuticals, and post-procedure support can create a competitive advantage and address the holistic needs of patients. Comprehensive care solutions often involve a combination of BPH devices, pharmaceuticals, and post-procedure support. This integrated approach can lead to better patient outcomes by addressing both the underlying condition and related symptoms more effectively. Patients with BPH may experience a range of symptoms, including urinary issues and discomfort. Comprehensive care solutions aim to provide a more comfortable and convenient experience by offering a complete package of services and support
By optimizing the treatment pathway and ensuring that patients receive appropriate care at each stage, comprehensive care solutions can help control healthcare costs. Early intervention and effective management can reduce the need for costly emergency care or surgical interventions
Restraint/Challenge
- Reimbursement Challenges
The reimbursement landscape for BPH treatments can be complex and subject to change. Variations in reimbursement policies and rates can affect the financial viability of certain procedures. Many BPH devices and treatments can be expensive. Patients often rely on health insurance coverage or government reimbursement programs to help cover the costs. When reimbursement is limited or denied, patients may be unable to afford the necessary BPH procedures or devices, leading to delayed or inadequate treatment
Reimbursement policies can vary among different insurance providers and government healthcare programs. This inconsistency in coverage can create confusion and make it difficult for patients and healthcare providers to determine which BPH devices and treatments are covered and to what extent
This North America benign prostatic hyperplasia devices market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the North America benign prostatic hyperplasia devices market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth
Recent Development
- In 2019, according to the American Journal of Men's Health (AJMH), globally, there were 11.26 million new cases and 1.86 million YLD due to BPH in 2019. The incidence of BPH increased by 105.7%, and YLD increased by 110.6% worldwide during 1990–2019.
North America Benign Prostatic Hyperplasia Devices Market Scope
The North America benign prostatic hyperplasia devices market is segmented on the basis of procedure type and end-user. The growth amongst these segments will help you analyse meager growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Procedure Type
- Transurethral Resection of the Prostate (TURP)
- Prostatic Urethral Lift (PUL)
- Prostatectomy, Laser Surgery
- Transurethral Microwave Therapy (TUMT)
- Transurethral Needle Ablation of the Prostate (TUNA)
- Prostatic Stenting/Implants
- Others
End-User
- Hospitals and Clinics
- Ambulatory Surgical Centers
- Others
North America Benign Prostatic Hyperplasia Devices Market Regional Analysis/Insights
North America benign prostatic hyperplasia devices market is analyzed, and market size insights and trends are provided by procedure type and end-user as referenced above.
The countries covered in the North America benign prostatic hyperplasia devices market report are U.S., Canada and Mexico.
North America dominates the benign prostatic hyperplasia devices market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period. This is due to the presence of FDA approved wound debridement devices and rising healthcare expenditure will further propel the market's growth rate in this region. In addition, favourable health remuneration policies, rise in chronic wounds, and a growing elderly population will further propel the market's growth rate in this region.
The country section of the report also provides individual market impacting factors and changes in market regulation that impact the current and future trends of the market. Data points such as down-stream and up-stream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of North America brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure Growth Installed Base and New Technology Penetration
The North America benign prostatic hyperplasia devices market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for North America benign prostatic hyperplasia devices market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the North America benign prostatic hyperplasia devices market. The data is available for historic period 2015-2020.
Competitive Landscape and North America Benign Prostatic Hyperplasia Devices Market Share Analysis
The North America benign prostatic hyperplasia devices market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the company’s focus related to North America benign prostatic hyperplasia devices market.
Some of the major players operating in the North America benign prostatic hyperplasia devices market are:
- KARL STORZ (Germany)
- OmniGuide Holdings, Inc. (U.S.),
- Olympus Corporation (Japan)
- Richard Wolf GmbH (Germany)
- Lumenis (Israel)
- Urologix, LLC (U.S.)
- Boston Scientific Corporation (U.S.)
- Coloplast Corp (U.S.)
- Medifocus Inc. (U.S.)
- biolitec AG (Germany)
- Teleflex Incorporated (U.S.)
- Urotech Devices (Singapore)
- BD (U.S.)
- PROCEPT BioRobotics Corporation (U.S.)
SKU-